Enveric Biosciences, Inc.
ENVB
$1.46
$0.042.47%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 12.21% | 11.63% | 8.38% | 1.26% | 6.15% |
| Total Depreciation and Amortization | -46.62% | -52.84% | -40.47% | -28.16% | -17.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -66.00% | -64.22% | -62.49% | -45.25% | -9.18% |
| Change in Net Operating Assets | -136.92% | -69.71% | 30.07% | 143.95% | 195.49% |
| Cash from Operations | -31.30% | -6.48% | -5.38% | 6.09% | 34.66% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 138.13% | 56.55% | 74.84% | 50.43% | 16.84% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 8.29% | -- | -- | -101.40% | -106.83% |
| Cash from Financing | 138.64% | 58.00% | 37.87% | 18.93% | -8.16% |
| Foreign Exchange rate Adjustments | -89.66% | -89.55% | -128.30% | -194.07% | -728.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 934.33% | 129.80% | 5,284.04% | 155.93% | 81.76% |